Skip to content

logo

SEARCH icon
  • Investing News
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Financial
  • Health
  • MORE
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Industrials
    • Food & Beverage
Search

SEARCH FOR AN ARTICLE

  • Investing News
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Financial
  • Health
  • MORE
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Industrials
    • Food & Beverage

logo

icon

      HomeBiotech

      Biotech

      BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
      Biotech

      BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

      August 28, 2026
      Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
      Biotech

      Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

      August 28, 2026
      HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
      Biotech

      HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

      August 28, 2026
      TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
      Biotech

      TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS

      August 27, 2026
      AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn’s Disease
      Biotech

      AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn’s Disease

      August 27, 2026
      Mesoblast Reports Substantial Revenue Growth to US$120M
      Biotech

      Mesoblast Reports Substantial Revenue Growth to US$120M

      August 27, 2026
      Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
      Biotech

      Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

      August 27, 2026
      Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
      Biotech

      Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

      August 26, 2026
      JATT III Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering
      Biotech

      JATT III Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering

      August 26, 2026
      SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
      Biotech

      SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

      August 26, 2026
      « 1 … 8 9 10 11 12 … 212 »

       

      LATEST NEWS

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from Stock Street News.

      I want e-mail alerts, updates, and offers and agree to the StockStreetNews privacy policy.

      Market Jar Media Inc. © 2026